Citi maintains ‘Buy' on Sun Pharma post Q4 with target price of Rs 2,220; bets on specialty push despite EPS cut
By Markets Desk Published on May 23, 2025, 08:08 IST
Citi has maintained its 'Buy' rating on Sun Pharmaceutical Industries with a target price of ₹2,220, noting that Q4FY25 results were largely in line with expectations. The brokerage remains optimistic about Sun's strategic pivot toward specialty therapies despite short-term EPS dilution.
Sun Pharma reported a 19% year-on-year decline in net profit to ₹2,153.9 crore, impacted by an exceptional loss of ₹361.6 crore. However, operationally, the company delivered solid growth — EBITDA rose 22.4% YoY to ₹3,715.9 crore, with margin expanding to 28.7% from 25.3% last year.
Citi pointed out that strength in India and emerging markets offset weakness in the US generics portfolio. Specialty revenue softness was anticipated due to channel filling and milestone-driven upsides in Q3, which had been flagged by the management earlier.
Citi was encouraged by management's positive commentary on the Most Favored Nation (MFN) pricing impact, which had been seen as a key overhang for the sector. While Sun's FY26 revenue guidance of mid-to-high single-digit growth reflects caution in light of regulatory and geopolitical uncertainties, the planned $100 million investment in launches like Leqselvi and Unloxcyt signals a ramp-up in the specialty business.
Despite a 6% cut in FY26 EPS estimates, Citi believes the investments are necessary to build long-term value.
Disclaimer: This article is based on the brokerage report by Citi. It does not constitute investment adv
Markets Desk at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Dow Strengthens Dividend Prospects Following Major Legal Victory in Canada
Dow Inc. (NYSE:DOW) is one of the 10 best dividend stocks according to Jim Cramer. On June 11, 2025, Citi reaffirmed its Hold rating on the stock but has adjusted the price target from $29 to $30. A technician operating state of the art machines manufacturing specialized packaging materials. Headquartered in Michigan, Dow Inc. (NYSE:DOW) is one of the world's leading manufacturers and suppliers of chemicals, plastics, and sealants. The company's products and services are used in multiple sectors, including packaging, infrastructure, mobility, and consumer care. With manufacturing sites in 31 countries, the company is a heavy investor in R&D with a special focus on areas like energy efficiency, sustainable packaging, and mobility. Citi's Hold rating and the price target adjustment on the stock arrive after a Canadian court order ordered Nova Chemicals to pay Dow Inc. (NYSE:DOW) an additional amount of $1.2 billion in damages. The judgment, arrived on June 10, was in relation to losses incurred by the company from a jointly owned ethylene asset in Joffre, Alberta, Canada. The judgment translated positively among the market experts, particularly after a fall in stock price on June 2, 2025, following the sale of 50% interest in DowAksa Advanced Composites Holdings BV (DowAksa) to Aksa Akrilik Kimya Sanayii A.Ş. Dow Inc. (NYSE:DOW) offers a dividend yield of 9.29%, thereby attracting investors seeking high and consistent income. However, the payout ratio of over 700% signals caution when investing in the stock. While we acknowledge the potential of DOW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Dow Strengthens Dividend Prospects Following Major Legal Victory in Canada
Dow Inc. (NYSE:DOW) is one of the 10 best dividend stocks according to Jim Cramer. On June 11, 2025, Citi reaffirmed its Hold rating on the stock but has adjusted the price target from $29 to $30. A technician operating state of the art machines manufacturing specialized packaging materials. Headquartered in Michigan, Dow Inc. (NYSE:DOW) is one of the world's leading manufacturers and suppliers of chemicals, plastics, and sealants. The company's products and services are used in multiple sectors, including packaging, infrastructure, mobility, and consumer care. With manufacturing sites in 31 countries, the company is a heavy investor in R&D with a special focus on areas like energy efficiency, sustainable packaging, and mobility. Citi's Hold rating and the price target adjustment on the stock arrive after a Canadian court order ordered Nova Chemicals to pay Dow Inc. (NYSE:DOW) an additional amount of $1.2 billion in damages. The judgment, arrived on June 10, was in relation to losses incurred by the company from a jointly owned ethylene asset in Joffre, Alberta, Canada. The judgment translated positively among the market experts, particularly after a fall in stock price on June 2, 2025, following the sale of 50% interest in DowAksa Advanced Composites Holdings BV (DowAksa) to Aksa Akrilik Kimya Sanayii A.Ş. Dow Inc. (NYSE:DOW) offers a dividend yield of 9.29%, thereby attracting investors seeking high and consistent income. However, the payout ratio of over 700% signals caution when investing in the stock. While we acknowledge the potential of DOW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Yahoo
17 hours ago
- Yahoo
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
